CC-CHOC (CTSA Consortium Child Health Oversight Committee)
CC-CHOC is a collaborative research consortium at all CTSA sites with Pediatric programs. In response to requests from Industry, CRO’s, government (NIH and FDA), and many investigators both within and outside the CTSA consortium, below are people who are looking for expertise and collaborators.
A Comparative Single-Dose Pharmacokinetic and Safety Study of Study Drug Between Infants, Children, and Adolescents with Hypertension and Healthy Adults
A Multicenter, Open-Label, Safety and Pharmacokinetic Study of Oral Codeine Sulfate Administration in Pediatric Subjects 2 years old through 17 years old with Post-procedural Pain
A Phase 1 Open-Label, Multicenter, Single and Multiple Ascending Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability in Subjects 6 to 17 Years Old with Schizophrenia Spectrum, Bipolar Spectrum, Autistic Spectrum Disorder, or Other Psychiatric Disorders
Open-label, multicenter study of the Safety, Pharmacokinetics and Efficacy study in Children from 7 to 16 Years of Age, Inclusive Who Require Continuous Opioid Analgesia for Moderate to Severe Pain
Collaboration to Improve Knowledge and Treatment of Plastic Bronchitis in Children
A Multicenter, Double-blind, Randomized, Placebo-Controlled, 4-armed Parallel Group Study to Evaluate the Safety and Efficacy of Study Drug 0.5-, 2.5-, and 5 mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents
A Multicenter, Double-blind, Randomized, Placebo-Controlled, 4-armed Parallel Group Study to Evaluate the Safety and Efficacy of Study Drug 0.5-, 2.5-, and 5 mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents
A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Study Drug Versus Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections
A Randomized, Double-Blind, Active-Controlled Efficacy and Safety Study of the Investigational Product Treatment and Withdrawal, Followed by an Open-Lable Extension, in Children 6 to Less Than 18 Years of Age with Hypertension
A Phase 2, Double-Blind, Randomized, Efficacy and Safety Comparison of Study Drug and Placebo in Pediatric Patients with Sickle Cell Disease
Dystrophic Epidermolysis Bullosa (DEB) Information
An open-label, multicenter, single-arm, Phase I dose-escalation with efficacy tail extension study of STUDY DRUG in pediatric patients with surgically incurable and unresectable Stage IIIC or Stage IV melanoma harbouring BRAFV600 mutations
Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Study Drug in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder
A Pediatric Sequential Dose-Escalation Double-blinded, Placebo-controlled, Phase 1 Study to Evaluate the Safety and Tolerability of Oral Suspension XXXX in Pediatric Patients with Crohn's Disease
Single Dose PK and PD Study of an investigational glucose lowering drug in children aged 10-17 wtih Type 2 Diabetes
A Phase III, Multicenter, Double-Blind, Randomized, Placebo and Metformin-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients with Type 2 Diabetes Mellitus
